MedCap AB (publ) Asset Resilience Ratio

Latest as of December 2025: 14.21%

MedCap AB (publ) asset resilience ratio. MedCap AB (publ) (MCAP) has an Asset Resilience Ratio of 14.21% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See MCAP cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Liquid Assets

Skr370.40 Million
≈ $39.86 Million USD Cash + Short-term Investments

Total Assets

Skr2.61 Billion
≈ $280.45 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio of MedCap AB (publ) (2016–2025)

Asset resilience ratio of MedCap AB (publ) from 2016 to 2025. This chart shows how MedCap AB (publ)'s Asset Resilience Ratio has changed over time. Read MCAP total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down MedCap AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see MedCap AB (publ) assets under control.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr370.40 Million 14.21%
Short-term Investments Skr0.00 0%
Total Liquid Assets Skr370.40 Million 14.21%

Asset Resilience Insights

  • Moderate Liquidity: MedCap AB (publ) has 14.21% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

MedCap AB (publ) Industry Peers by Asset Resilience Ratio

Compare MedCap AB (publ)'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Shenzhen New Industries Biomedical
SHE:300832
Medical Devices 9.95%
Double Medical Technology Inc
SHE:002901
Medical Devices 12.59%
BMC Medical Co. Ltd. A
SHE:301367
Medical Devices 44.96%
Emvision Medical Devices Ltd
AU:EMV
Medical Devices 0.06%
Hironic Co. Ltd
KQ:149980
Medical Devices 17.42%
DRGEM Corporation
KQ:263690
Medical Devices 2.12%
Oncosil Medical Ltd
AU:OSL
Medical Devices 0.00%
Adherium Ltd
AU:ADR
Medical Devices 15.45%

MedCap AB (publ) Asset Resilience Ratio by Year (2016–2025)

MedCap AB (publ) asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for MedCap AB (publ).

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 14.21% Skr370.40 Million
≈ $39.86 Million
Skr2.61 Billion
≈ $280.45 Million
-4.37pp
2024-12-31 18.58% Skr370.10 Million
≈ $39.83 Million
Skr1.99 Billion
≈ $214.31 Million
+7.26pp
2023-12-31 11.32% Skr188.20 Million
≈ $20.25 Million
Skr1.66 Billion
≈ $178.88 Million
-5.20pp
2022-12-31 16.53% Skr236.20 Million
≈ $25.42 Million
Skr1.43 Billion
≈ $153.82 Million
+4.58pp
2021-12-31 11.95% Skr139.70 Million
≈ $15.03 Million
Skr1.17 Billion
≈ $125.86 Million
-1.60pp
2020-12-31 13.55% Skr146.50 Million
≈ $15.77 Million
Skr1.08 Billion
≈ $116.37 Million
+11.10pp
2019-12-31 2.45% Skr20.60 Million
≈ $2.22 Million
Skr842.30 Million
≈ $90.64 Million
+0.23pp
2018-12-31 2.21% Skr14.80 Million
≈ $1.59 Million
Skr668.90 Million
≈ $71.98 Million
-8.01pp
2017-12-31 10.22% Skr61.33 Million
≈ $6.60 Million
Skr600.20 Million
≈ $64.59 Million
+2.66pp
2016-12-31 7.56% Skr42.59 Million
≈ $4.58 Million
Skr563.16 Million
≈ $60.61 Million
--
pp = percentage points

About MedCap AB (publ)

ST:MCAP Sweden Medical Devices
Market Cap
$891.39 Million
Skr8.28 Billion SEK
Market Cap Rank
#9037 Global
#151 in Sweden
Share Price
Skr551.50
Change (1 day)
-1.34%
52-Week Range
Skr453.00 - Skr600.50
All Time High
Skr670.00
About

MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, add-on acquisitions, growth capital, middle market, mature, turnarounds, and buyout. It prefers to invest in Biotechnology; Life sciences; Pharmaceuticals; MedTech including healthcare equipment, software, components, and packaging solutions for life science products; an… Read more